The influence of irbesartan on biomarkers of renal function and oxidative stress

The influence of irbesartan on biomarkers of renal function and oxidative stress - The influence of irbesartan on renal function

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013065

Enrollment

Registered

2014-02-05

Start date

2014-02-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

Irbesartan Amlodipine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients of hypertension who need medication

Exclusion criteria

Exclusion criteria: (a) patietns exceeding or under the age limit (b) patietns in whom the side effect of irbesartan possibly occure (c) patietns with past heart failure (d) patietns with ejection fraction under 40% (e) patietns with other reasons not appropriate for the study

Design outcomes

Primary

Measure	Time frame
The changes of renal biomarker of liver-type fatty acid binding protein (L-FABP)	—

Countries

Japan

Contacts

Public ContactNobuyuki Masaki

National Defense Medical College Department of cardiology

nmasaki@ndmc.ac.jp0429-95-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026